Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc (NASDAQ:CORT), filed a Form 4 on August 18, 2026, disclosing two transactions in common stock dated August 17, 2026: a gift of 125 shares and an open-market sale of 10,000 shares.
Key Highlights
- Sale of 10,000 shares: Robb disposed of 10,000 shares of common stock at a weighted average price of $116.2572, with individual sale prices ranging from $116.00 to $116.54 per share.
- Gift of 125 shares: Robb disposed of 125 shares via a gift (transaction code G) at $0.00, reducing his direct holdings.
- Direct holdings after transactions: Robb directly beneficially owned 13,426 shares following the reported transactions, including shares underlying unvested restricted stock awards.
- Indirect holdings: Robb indirectly held 39,716 shares through the Gary Charles Robb TTE Robb Revocable Trust, plus 15,571 shares in each of two custodial accounts for children, as of the transaction date.
- Unvested restricted stock awards: The 13,426 direct shares include 251, 224, 499, and 776 shares underlying unvested restricted stock awards granted on September 2, 2025, December 1, 2025, March 2, 2026, and June 1, 2026, respectively, each vesting on the one-year anniversary of the grant date.
Robb's August 2026 Transactions in Corcept Therapeutics Common Stock
According to the filing, Gary Charles Robb, serving as Chief Business Officer of Corcept Therapeutics Inc, reported two transactions on August 17, 2026. The first was a disposition of 125 shares coded as a gift (transaction code G) at a price of $0.00. The second was a sale (transaction code S) of 10,000 shares at a weighted average price of $116.2572. The filing noted that actual sale prices ranged from $116.00 to $116.54 per share, and that exact share counts at each price are available from the issuer upon request.
Following these transactions, the filing reported Robb's direct beneficial ownership at 13,426 shares. That figure includes unvested restricted stock awards: 251 shares granted September 2, 2025; 224 shares granted December 1, 2025; 499 shares granted March 2, 2026; and 776 shares granted June 1, 2026. According to the filing, "100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."
The filing also disclosed indirect holdings. Robb held 39,716 shares indirectly through the Gary Charles Robb TTE Robb Revocable Trust, of which he is trustee. Additionally, he is custodian for two separate custodial accounts, each holding 15,571 shares, established under the Uniform Transfers to Minors Act for two children. The form was signed by Joseph Douglas Lyon as attorney-in-fact for Gary Charles Robb and filed on August 18, 2026.
What Was Disclosed
The filing reported a gift of 125 shares at $0.00 and a sale of 10,000 shares at a weighted average of $116.2572 by Corcept Therapeutics' Chief Business Officer on August 17, 2026, along with post-transaction beneficial ownership figures across direct and indirect accounts.



Please wait processing your request...